Clinical Study
Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines
Table 1
Characteristics of study groups.
| | | Nontreated cells | Statins | Aspirin | Statin + aspirin |
| | Men () | 1504 | 440 | 160 | 304 | | Age (years) | 67 | 68 | 68 | 67 | | BMI (Kg/m2) | 26.9 | 27.6 | 27.2 | 27.8 | | Serum PSA (ng/mL) | 6.9 | 6.7 | 6.9 | 6.8 | | Positive DRE (%) | 540 (36) | 160 (36) | 50 (31) | 106 (35) | | Gleason score < 7 (%) | 112 (7.4) | 32 (7.3) | 14 (8.8) | 18 (6) | | Gleason score = 7 (%) | 273 (18.2) | 76 (17.3) | 38 (23.8) | 45 (14.8) | | Gleason score > 7 (%) | 155 (10.3) | 43 (9.8) | 18 (11.2) | 24 (7.9) |
|
|
BMI: body mass index, PSA: prostate specific antigen, and DRE: digital rectal examination.
|
